UK has doubts on UPC but commits to SPCs
The UK’s participation in Europe’s unified patent court (UPC) hangs in the balance in the event of no deal being reached on the UK’s ‘Brexit’ departure from the European Union (EU) in March 2019, according to guidance issued by the UK government on intellectual-property (IP) issues relating to pharmaceuticals, including patents and supplementary protection certificates (SPCs). But even with no deal, the UK will continue to offer SPCs.
You may also be interested in...
With a constitutional challenge still pending in Germany, and lingering uncertainties over Brexit, Germany's federal government appears to have little idea when a planned European Unified Patent Court could come into effect.
With a constitutional challenge still pending in Germany, and lingering uncertainties over Brexit, Germany’s federal government appears to have little idea when a planned European unified patent court could come into effect.
Panellists at the UK’s Westminster Health Forum conference on Biosimilars in the NHS united over concerns of a no-deal Brexit and what it would mean for generics and biosimilars producers.